IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1126-1150 out of 1258.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

Public Release: 11-Mar-2014
British Journal of Cancer
New prognostic test for breast cancer could improve patient treatment
A study by researchers in Nottingham has developed a new clinical test for breast cancer which aims to improve patient treatment.
Medical Research Council

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-011-595-15793
University of Nottingham

Public Release: 11-Mar-2014
Proceedings of the National Academy of Sciences
Cancer cells don't take 'drunken' walks through the body
Biologists have believed that cancers cells spread through the body in a slow, aimless fashion, resembling a drunk who can't walk straight. They now know that's true in a flat petri dish, but not in the three-dimensional space of an actual body.
National Institutes of Health

Contact: Phil Sneiderman
prs@jhu.edu
443-997-9907
Johns Hopkins University

Public Release: 11-Mar-2014
Anesthesiology
Anesthetic technique improves quality of recovery for women having breast cancer surgery
Anesthesiologists using a technique similar to a dental freeze can improve the quality of recovery and decrease recovery time for breast cancer surgery patients, according to a new study.
Ontario Ministry of Health and Long Term Care/Alternate Funding Plan Innovation Fund

Contact: Geoff Koehler
koehlerg@smh.ca
416-864-6060 x6537
St. Michael's Hospital

Public Release: 11-Mar-2014
Nature Communications
New technique uses ATP as trigger for targeted anti-cancer drug delivery
Biomedical engineering researchers have developed a new technique that uses adenosine-5'-triphosphate, the so-called 'energy molecule,' to trigger the release of anti-cancer drugs directly into cancer cells. Early laboratory tests show it increases the effectiveness of drugs targeting breast cancer.
National Institutes of Health

Contact: Matt Shipman
matt_shipman@ncsu.edu
919-515-6386
North Carolina State University

Public Release: 11-Mar-2014
Journal of Clinical Investigation
Study finds CT scans predict chemotherapy response in pancreatic cancer
Computed tomography scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research from the University of Texas MD Anderson Cancer Center, the scans also reflect how well chemotherapy will penetrate the tumor, predicting the effectiveness of treatment.

Contact: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center

Public Release: 11-Mar-2014
PLOS ONE
Researchers slow pancreatic cancer growth by blocking key enzyme
A research team from Imperial College London has shown that blocking the function of an enzyme known as Hhat slows the growth and spread of pancreatic cancer, by preventing a protein called Hedgehog from stimulating nearby normal cells to help the cancer.
Pancreatic Cancer Research Fund

Contact: Becky Tanner
beckytanner@pcrf.org.uk
44-020-836-01119
Pancreatic Cancer Research Fund

Public Release: 10-Mar-2014
Cancer Epidemiology, Biomarkers & Prevention
Young skin cancer survivors at risk of other cancers later
Young people who have been diagnosed with non-melanoma skin cancer related to sun exposure, under the age of 25, face a higher risk of developing melanoma and other cancers later in life, a UK study has shown.

Contact: Anne Rahilly
arahilly@unimelb.edu.au
61-390-355-380
University of Melbourne

Public Release: 10-Mar-2014
Journal of Proteome Research
New sugar-test to reduce false-positive cancer diagnoses
The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen have developed a method able to halve the number of false-positives. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.

Contact: Jes Andersen
jean@science.ku.dk
45-23-60-11-40
University of Copenhagen

Public Release: 10-Mar-2014
Proceedings of the National Academy of Sciences
Several FDA-approved anti-cancer drugs induce stem cell tumors, perhaps thwarting therapy
In a surprise finding, University of Massachusetts Amherst and Harvard researchers discovered that several chemotherapeutics that do stop fast growing tumors have the opposite effect on stem cells in the same animal, causing them to divide too rapidly. Not only is the finding of clinical interest, but with this study they successfully used a new non-traditional tool for assessing drugs using stem cells in the fruit fly gut, the first author says.
National Institutes of Health Challenge Grant

Contact: Janet Lathrop
jlathrop@admin.umass.edu
413-545-0444
University of Massachusetts at Amherst

Public Release: 10-Mar-2014
Cancer
Targeted drug may prolong survival of patients with cervical cancer
A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
201-748-6358
Wiley

Public Release: 10-Mar-2014
Journal of Clinical Oncology
New prostate cancer treatment convenient, less expensive, but may be riskier
A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers -- a higher rate of urinary complications.
NIH/National Cancer Institute

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University

Public Release: 10-Mar-2014
Journal of National Cancer Institute
PSA-testing and early treatment decreases risk of prostate cancer death
Mortality in prostate cancer is lower in areas with frequent use of PSA testing compared with areas with little testing shows a study published online today in Journal of the National Cancer Institute by researchers from Umea University, Sweden and Memorial Sloan Kettering Cancer Center, New York, N.Y., USA.

Contact: Pär Stattin
par.stattin@umu.se
46-736-205-251
Umea University

Public Release: 10-Mar-2014
Journal of Clinical Investigation
JCI online ahead of print table of contents for March 10, 2014
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers published online, March 10, 2014 in the JCI: 'Identification of a broadly neutralizing HIV-1 antibody in a lupus patient,' 'Evaluating disease-associated protein turnover kinetics,' 'Transport properties of pancreatic cancer describe gemcitabine delivery and response,' 'HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers,' 'iNKT cells require TSC1 for terminal maturation and effector lineage fate decisions,' and more.

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 10-Mar-2014
Blood
Study finds pill may represent promising treatment for stubborn blood cancers
A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports published online today in Blood, the journal of the American Society of Hematology.

Contact: Kaitlin Bressler
kbressler@hematology.org
202-552-4952
American Society of Hematology

Public Release: 10-Mar-2014
Nature
UV light aids cancer cells that creep along the outside of blood vessels
A new study by UCLA scientists and colleagues adds further proof to earlier findings by Dr. Claire Lugassy and Dr. Raymond Barnhill of UCLA's Jonsson Comprehensive Cancer Center that deadly melanoma cells can spread through the body by creeping like tiny spiders along the outside of blood vessels without ever entering the bloodstream.

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles

Public Release: 10-Mar-2014
Cancer Research
A signal to spread: Wistar scientists identify potent driver of metastasis
An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body. Wistar scientists have also developed and patented a monoclonal antibody that may one day be used as a prognostic test to see if tumors have LIMD2, and plans are underway to create inhibitors -- potential drugs that may target cells that produce LIMD2.
National Institutes of Health, Samuel Waxman Cancer Research Foundation, Susan G. Komen, O'Neill Foundation for Melanoma

Contact: Greg Lester
glester@wistar.org
215-898-3943
The Wistar Institute

Public Release: 10-Mar-2014
New England Journal of Medicine
Moffitt Cancer Center pioneers worldwide standard in diagnosing melanoma
Moffitt Cancer Center researchers have been instrumental in making significant improvements to the diagnostic procedure called sentinel node biopsy for melanoma patients and teaching this procedure to physicians from around the world.
NIH/National Cancer Institute, National Institutes of Health, Australia and New Zealand Melanoma Trials Group

Contact: Kimberly Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 10-Mar-2014
BMJ
'Older people denied proper access to cancer care' according to Queen's study
Older people are being denied proper access to cancer care, according to a study by Queen's University Belfast academic, professor Mark Lawler of the Centre for Cancer Research and Cell Biology. Professor Lawler said: 'There is increasing evidence that elderly patients are being 'undertreated,' leading to a 'survival gap' between older and younger patients. Professor Lawler's findings are published in an editorial in the BMJ and titled, 'Ageism In Cancer Care: We Need to Change The Mindset.'

Contact: Anne-Marie Clarke
amclarke2@gmail.com
44-028-909-75320
Queen's University Belfast

Public Release: 9-Mar-2014
Nature Genetics
Mutations in leukemia gene linked to new childhood growth disorder
Mutations in a gene associated with leukemia cause a newly described condition that affects growth and intellectual development in children, new research reports. A study led by scientists at The Institute of Cancer Research, London, identified mutations in the DNA methyltransferase gene, DNMT3A, in 13 children.

Contact: Henry French
henry.french@icr.ac.uk
020-715-35312
Institute of Cancer Research

Public Release: 9-Mar-2014
Nature Chemical Biology
UNC researchers create new tool to unravel the mysteries of metastasis
Researchers at the UNC School of Medicine have devised a new biochemical technique that will allow them and other scientists to delve much deeper than ever before into the specific cellular circuitry that keeps us healthy or causes disease.
National Institutes of Health

Contact: Mark Derewicz
mark.derewicz@unch.unc.edu
919-923-0959
University of North Carolina Health Care

Public Release: 7-Mar-2014
11th International Conference on Urban Health
New approach to prostate cancer screening needed
Manchester researchers surveyed more than 1,000 men and over 100 GPs about whether they would be happy with a risk-based approach to prostate cancer screening. The findings show over 80 percent of men expressed strong support and 77 percent of GPs were supportive.

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 7-Mar-2014
Journal of the National Cancer Institute
Cells appearing normal may actually be harbingers of lung cancer
Airways near lung tumors provide clues to the genetics of cancer.

Contact: Scott Merville
smerville@mdanderson.rg
713-792-0661
University of Texas M. D. Anderson Cancer Center

Public Release: 7-Mar-2014
Journal of National Cancer Institute
Bone turnover markers predict prostate cancer outcomes
Biomarkers for bone formation and resorption predict outcomes for men with castration-resistant prostate cancer, a team of researchers from UC Davis and their collaborators have found.
National Institutes of Health

Contact: Dorsey Griffith
dorsey.griffith@ucdmc.ucdavis.edu
916-734-9118
University of California - Davis Health System

Public Release: 7-Mar-2014
Oncotarget
Anti-psychotic medications offer new hope in the battle against glioblastoma
Researchers at the University of California, San Diego School of Medicine have discovered that Food and Drug Administration-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma.
Sontag Foundation, Burroughs Wellcome Foundation, Kimmel Foundation, Forbeck Foundation

Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 7-Mar-2014
SPIE DSS
Journal of Biomedical Optics
New high-tech glasses detect cancer cells during surgery
Scientists at Washington University School of Medicine in St. Louis and the University of Arizona in Tucson led by Samuel Achilefu have created a pair of high-tech glasses that help surgeons visualize cancer cells during surgeries. The technology, reported in the SPIE Journal of Biomedical Optics, incorporates custom video and a head-mounted display capable of capturing signal from any fluorescent molecular agent injected into a patient that attaches to cancer cells, making them glow.
NIH/National Cancer Institute, National Institutes of Health

Contact: Amy Nelson
amy@spie.org
360-685-5478
SPIE--International Society for Optics and Photonics

Showing releases 1126-1150 out of 1258.

<< < 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

  Search News Releases

     

 

 

EurekAlert!